AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma

Hepatology, Год журнала: 2023, Номер 78(6), С. 1922 - 1965

Опубликована: Май 18, 2023

Singal, Amit G.; Llovet, Josep M.; Yarchoan, Mark; Mehta, Neil; Heimbach, Julie K.; Dawson, Laura A.; Jou, Janice H.; Kulik, Agopian, Vatche Marrero, Jorge Mendiratta-Lala, Mishal; Brown, Daniel B.; Rilling, William S.; Goyal, Lipika; Wei, Alice C.; Taddei, Tamar H. Author Information

Язык: Английский

---

Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy

Nature Reviews Clinical Oncology, Год журнала: 2023, Номер 20(12), С. 864 - 884

Опубликована: Окт. 26, 2023

Язык: Английский

---

Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment

Nature Reviews Gastroenterology & Hepatology, Год журнала: 2023, Номер 20(8), С. 487 - 503

Опубликована: Март 17, 2023

Язык: Английский

---

Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study

Clinical and Molecular Hepatology, Год журнала: 2023, Номер 29(2), С. 433 - 452

Опубликована: Янв. 4, 2023

Background/Aims: Global distribution of dominant liver cancer aetiologies has significantly changed over the past decades. This study analyzed updated temporal trends and sociodemographic status in 204 countries territories from 1990 to 2019.Methods: The Burden Disease 2019 report was used for statistical analysis. In addition, we performed stratification analysis five quintiles using index 21 geographic regions.Results: crude numbers disease-adjusted life years (DALYs) deaths increased during period (DALYs; 11,278,630 12,528,422 2019, deaths; 365,215 484,577 2019). However, Age-standardized DALY mortality rates decreased. Hepatitis B virus (HBV) remains leading cause DALYs mortality, followed by hepatitis C (HCV), alcohol consumption, non-alcoholic steatohepatitis/non-alcoholic fatty disease (NASH/NAFLD). Although due HBV HCV have decreased, consumption NASH/NAFLD increased. population East Asia region had highest rates, high-income Asia-Pacific Central populations. regions showed a decrease period, Asia. High-income North American Australasian populations also significant increase DALY. Conclusions: Liver an ongoing global threat. burden associated with is markedly increasing projected continuously increase.

Язык: Английский

---

EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma

Journal of Hepatology, Год журнала: 2024, Номер unknown

Опубликована: Дек. 1, 2024

Язык: Английский

---

Metabolic dysfunction-associated steatotic liver disease and its link to cancer

Metabolism, Год журнала: 2024, Номер 160, С. 156004 - 156004

Опубликована: Авг. 24, 2024

Язык: Английский

---

Effect of cofactors on NAFLD/NASH and MAFLD. A paradigm illustrating the pathomechanics of organ dysfunction

Metabolism and Target Organ Damage, Год журнала: 2022, Номер 2, С. 12 - 12

Опубликована: Янв. 1, 2022

Primary nonalcoholic fatty liver disease (NAFLD) is bi-directionally associated with the metabolic syndrome and its constitutive features ("factors": impaired glucose disposal, visceral obesity, arterial hypertension, dyslipidemia). Secondary NAFLD occurs due to endocrinologic disturbances or other cofactors. This nosography tends be outdated by novel definition of (MAFLD). Irrespective nomenclature, this condition exhibits a remarkable pathogenic heterogeneity unpredictable clinical outcomes which are heavily influenced histology changes. Genetics epigenetics, lifestyle habits [including diet physical (in)activity] immunity/infection appear major cofactors that modulate NAFLD/MAFLD outcomes, including organ dysfunction owing cirrhosis hepatocellular carcinoma, type 2 diabetes, chronic kidney disease, heart failure, sarcopenia. The identification for may help understand reliably support inherently personalized medicine approaches research priority, thus paving way innovative treatment strategies.

Язык: Английский

---

MAFLD: an optimal framework for understanding liver cancer phenotypes

Journal of Gastroenterology, Год журнала: 2023, Номер 58(10), С. 947 - 964

Опубликована: Июль 20, 2023

Hepatocellular carcinoma has a substantial global mortality burden which is rising despite advancements in tackling the traditional viral risk factors. Metabolic (dysfunction) associated fatty liver disease (MAFLD) most prevalent disease, increasing parallel with epidemics of obesity, diabetes and systemic metabolic dysregulation. MAFLD major factor behind this sustained rise HCC incidence, both as single entity often via synergistic interactions other diseases. Mechanisms MAFLD-related are complex but crucially underpinned by dysregulation variable contributions from interacting modifiers related to environment, genetics, dysbiosis immune distinct clinical presentation, notably its common occurrence non-cirrhotic disease. This just one several challenges effective surveillance programmes. The response immune-checkpoint therapy currently controversial, further complicated high prevalence individuals aetiologies. In review, we highlight current data on epidemiology, characteristics, outcomes screening controversies. addition, concepts that have arisen because paradigm such MAFLD/NAFLD non-overlapping groups, dual aetiology tumours sub-phenotypes reviewed.

Язык: Английский

---

Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients

Hepatology International, Год журнала: 2024, Номер 18(S2), С. 922 - 940

Опубликована: Июль 16, 2024

Язык: Английский

---

Metabolic dysfunction-associated steatotic liver disease and extrahepatic gastrointestinal cancers

Metabolism, Год журнала: 2024, Номер 160, С. 156014 - 156014

Опубликована: Авг. 24, 2024

Язык: Английский

---